Solid Biosciences, LLC Logo

# Solid Biosciences Announces Upcoming Preclinical Data Presentations

May 15, 2018

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) held May 16-19, 2018 in Chicago.

**Oral Presentations:**

- AAV Micro-Dystrophin Therapy Ameliorates Muscular Dystrophy in Young Adult Duchenne Muscular Dystrophy Dogs for Up to Thirty Months Following Injection
  *Abstract Number:* 8
  *Date/Time:*Wednesday, May 16th at 10:45 a.m. CT
- Identification of Novel AAV Capsids for Skeletal Muscle Gene Transfer By In Vivo Selection in Humanized Mice
  *Abstract Number:* 355
  *Date/Time:*Thursday, May 17th at 4:30 p.m. CT

**Poster Presentations:**

- Assessing Anti-Dystrophin T-Cell Responses by Elispot Following AAV9-Microdystrophin Gene Therapy in Dogs
  *Abstract Number:* 219
  *Date/Time:*Wednesday, May 16th at 5:30 p.m. CT
- In Vivo Comparison of the Biological Potency of rAAV9-Microdystrophin Made by Transient Transfection and a Scalable Herpesvirus System
  *Abstract Number:* 626
  *Date/Time:*Thursday, May 17th at 5:15 p.m. CT
- In Silico Platform for the Design and Generation of Novel Muscle Promoters: In Vitro Validation
  *Abstract Number:* 869
  *Date/Time:*Friday, May 18th at 5:45 p.m. CT
- Preclinical Evaluation of SGT-001 Microdystrophin Gene Transfer for Duchenne Muscular Dystrophy
  *Abstract Number:* 854
  *Date/Time:*Friday, May 18th at 5:45 p.m. CT
- Complementary Techniques to Evaluate Microdystrophin Expression in Duchenne Muscular Dystrophy Gene Therapy Studies
  *Abstract Number:* 868
  *Date/Time:*Friday, May 18th at 5:45 p.m. CT

**About Solid Biosciences**
Solid Biosciences is a life science company focused solely on finding meaningful therapies for Duchenne muscular dystrophy (DMD). Founded by those touched by the disease, Solid is a center of excellence for DMD, bringing together experts in science, technology and care to drive forward a portfolio of candidates that have life-changing potential. Solid is progressing programs across four scientific platforms: Corrective Therapies, Disease-Modifying Therapies, Disease Understanding and Assistive Devices. Solid's lead clinical candidate for DMD is a novel adeno-associated viral (AAV) vector-mediated microdystrophin gene transfer called SGT-001. The Phase I/II clinical trial for SGT-001, IGNITE DMD, is currently on clinical hold. For more information, please visit www.solidbio.com.

**Contact:**
Solid Biosciences
Kate Niazi-Sai
+1 617-337-4680
media@solidbio.com
investors@solidbio.com

Primary Logo

Source: Solid Biosciences Inc.